Moody Aldrich Partners LLC Purchases New Position in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Moody Aldrich Partners LLC purchased a new position in MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 55,245 shares of the company's stock, valued at approximately $2,158,000. Moody Aldrich Partners LLC owned approximately 0.09% of MoonLake Immunotherapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Deutsche Bank AG raised its position in MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after acquiring an additional 338 shares in the last quarter. Birchview Capital LP bought a new stake in MoonLake Immunotherapeutics in the fourth quarter worth about $217,000. KLP Kapitalforvaltning AS bought a new stake in MoonLake Immunotherapeutics in the fourth quarter worth about $244,000. PEAK6 LLC bought a new stake in MoonLake Immunotherapeutics in the fourth quarter worth about $271,000. Finally, Mariner LLC bought a new stake in MoonLake Immunotherapeutics in the fourth quarter worth about $272,000. 93.85% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MLTX has been the topic of a number of analyst reports. Wedbush reissued an "outperform" rating and issued a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Royal Bank Of Canada reissued an "outperform" rating and issued a $67.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 3rd. Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target on the stock in a research note on Monday, May 19th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 13th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $74.50.

MoonLake Immunotherapeutics Stock Down 2.8%

NASDAQ:MLTX traded down $1.39 on Monday, hitting $47.50. 496,401 shares of the company's stock traded hands, compared to its average volume of 385,496. The company has a current ratio of 21.11, a quick ratio of 21.11 and a debt-to-equity ratio of 0.18. MoonLake Immunotherapeutics has a 1 year low of $31.42 and a 1 year high of $58.26. The firm has a 50-day moving average price of $42.55 and a 200-day moving average price of $42.68. The company has a market cap of $3.04 billion, a PE ratio of -20.65 and a beta of 1.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.13. During the same period in the previous year, the firm posted ($0.22) EPS. Equities analysts anticipate that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.